Recon: FDA approves new Bristol Myers cancer immunotherapy; VRBPAC to discuss boosters, strain selection at 6 April meeting

• FDA advisers to discuss COVID vaccine boosters in April (Reuters)
• FDA approves new Bristol Myers cancer immunotherapy (Reuters) (Fierce)
• Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones ‘ringing off the hook’ (Fierce) (Endpoints)
• Marinus Pharmaceuticals Gets FDA Approval for Ztalmy (Bloomberg)
• Bristol-Myers Sues AstraZeneca for Profits Lost to Imfinzi Sales (Bloomberg)
• WH Reviewing FDA’s Long-Awaited Rx-To-OTC Proposed Rule (Inside Health Policy)
• Warren Bid to Grab Xtandi Cancer Drug Patents Gets Firm Rebuke (Bloomberg)
• Vaccines remained highly effective at preventing serious illness and death during omicron surge, CDC report says (Washington Post)
• Boosters Become Big Pharma Free-for-All With More Shots Coming (Bloomberg)

• New EMA Chair Pledges Agility, Responsiveness & Solidarity In Turbulent Times (The Pink Sheet)
• Pharma Companies Are Suspending Trials In Russia - But For Practical More Than Ethical Reasons (Scrip)
• Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug (Reuters)
• EMA Assessing 'Slightly' Raised Heart Attack Risk With Two COVID-19 Vaccines (The Pink Sheet)
• Aeterna the latest company to report trial delays brought on by Russia’s war in Ukraine (Fierce)
• Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine (Reuters)

• The Covid-19 vaccine market is getting crowded — as demand begins to wane (STAT)
• South Korea to buy 10 million doses of SK Bioscience's COVID vaccine (Reuters)
• AstraZeneca COVID drug neutralises Omicron sub-variants in lab study (Reuters)
• French HAS health authority recommends second Covid-19 booster jab for older people with health risks (Reuters)
• Moderna to supply additional 7 million doses of COVID booster vaccine to Switzerland (Reuters)

• Considerations For Using Established Versus Novel Endpoints In Decentralized Trials (The Pink Sheet)
• Sanofi Seeks Independence For API Unit Despite Stormy Market (Scrip)
• Bavarian Nordic Deal Opens Up Potential China Market For RSV Vaccine (Scrip)
• Pfizer CEO to haul in almost $50M in compensation in 2021 and 2022 (Endpoints)
• ImmunoGen’s ovarian cancer comeback not as rosy as expected as progression-free survival lags (Endpoints)
• Teva CEO Kåre Schultz brought home $14.7M last year, soaring past some of Europe's top-paid pharma execs (Endpoints)

• Compliance Corner: 4 Things You Should Do Now To Prep For FDA’s New QMSR Reg (MedTech Insight)
• FMC's US division Health Partners in $2.4 bln three-way merger (Reuters)
• Workshop Offers Glimpse At Future Of Hospital 3D Printing (MedTech Insight)
• MIT, Mass General researchers develop handheld robot for tapping into blood vessels (Fierce)
• Money flows into addiction tech, but will it curb soaring opioid overdose deaths (Fierce)
• Minute Insight: First Live Images Of Alpha-Synuclein Raise Hope For Improved Neurological Diagnostics (MedTech Insight)

• New Patent Battles Emerge Over What Lipid Technology Is Used In mRNA COVID-19 Vaccines (The Pink Sheet)
• Illumina sues Guardant Health, claiming founders stole cancer testing trade secrets (Fierce)
• Becton, McKesson, Cardinal Win Antitrust Appeal Over Syringes (Bloomberg)
• Bad Bargain? Old Opioid Deal Haunts Fla. AG As Trial Nears (Law360)